Fibronectin, the FNIII domain, and artificial antibodies

Author(s):  
Harold P Erickson
Keyword(s):  
2021 ◽  
Author(s):  
Jun Hosoe ◽  
Yuki Kawashima Sonoyama ◽  
Fuyuki Miya ◽  
Hiroko Kadowaki ◽  
Ken Suzuki ◽  
...  

We previously reported that genotype-phenotype correlations in 12 missense variants causing severe insulin resistance, located in the second and third fibronectin type III (FnIII) domains of the insulin receptor (INSR), containing the α-β cleavage and part of insulin-binding sites. This study aimed to identify genotype-phenotype correlations in FnIII domain variants of IGF1R, a structurally related homolog of INSR, which may be associated with growth retardation, using the recently reported crystal structures of IGF1R. A structural bioinformatics analysis of five previously reported disease-associated heterozygous missense variants and a likely benign variant in the FnIII domains of IGF1R predicted that the disease-associated variants would severely impair the hydrophobic core formation and stability of the FnIII domains or affect the α-β cleavage site, while the likely benign variant would not affect the folding of the domains. A functional analysis of these variants in CHO cells showed impaired receptor processing and autophosphorylation in cells expressing the disease-associated variants, but not in those expressing the wild-type form or the likely benign variant. These results demonstrated genotype-phenotype correlations in the FnIII domain variants of <i>IGF1R</i>, which are presumably consistent with<i> </i>those of <i>INSR</i> and would help in the early diagnosis of patients with disease-associated <i>IGF1R</i> variants.


2021 ◽  
Vol 11 ◽  
Author(s):  
Atsushi Takatori ◽  
Shamim Hossain ◽  
Atsushi Ogura ◽  
Jesmin Akter ◽  
Yohko Nakamura ◽  
...  

Receptor tyrosine kinases (RTKs) receive different modulation before transmitting proliferative signals. We previously identified neuronal leucine-rich repeat 1 (NLRR1) as a positive regulator of EGF and IGF-1 signals in high-risk neuroblastoma cells. Here, we show that NLRR1 is up-regulated in various adult cancers and acts as a key regulator of tumor cell proliferation. In the extracellular domains of NLRR1, fibronectin type III (FNIII) domain is responsible for its function to promote cell proliferation. We generated monoclonal antibodies against the extracellular domains of NLRR1 (N1mAb) and screened the positive N1mAbs for growth inhibitory effect. The treatment of N1mAbs reduces tumor cell proliferation in vitro and in vivo, and sensitizes the cells to EGFR inhibitor, suggesting that NLRR1 is a novel regulatory molecule of RTK function. Importantly, epitope mapping analysis has revealed that N1mAbs with growth inhibitory effect recognize immunoglobulin-like and FNIII domains of NLRR1, which also indicates the importance of FNIII domain in the function of NLRR1. Thus, the present study provides a new insight into the development of a cancer therapy by targeting NLRR1 as a modulator of proliferative signals on cellular membrane of tumor cells.


Hybridoma ◽  
2010 ◽  
Vol 29 (1) ◽  
pp. 13-16 ◽  
Author(s):  
Yu-Cai Wang ◽  
Lian-He Zheng ◽  
Bao-An Ma ◽  
Yong Zhou ◽  
Qing-Yu Fan

2010 ◽  
Vol 19 (11) ◽  
pp. 2231-2239 ◽  
Author(s):  
Shulin Zhuang ◽  
Apichart Linhananta ◽  
Hongbin Li

2018 ◽  
Vol 314 (6) ◽  
pp. H1179-H1191 ◽  
Author(s):  
Dan F. Smelter ◽  
Willem J. de Lange ◽  
Wenxuan Cai ◽  
Ying Ge ◽  
J. Carter Ralphe

Cardiac myosin-binding protein C (cMyBP-C) is a functional sarcomeric protein that regulates contractility in response to contractile demand, and many mutations in cMyBP-C lead to hypertrophic cardiomyopathy (HCM). To gain insight into the effects of disease-causing cMyBP-C missense mutations on contractile function, we expressed the pathogenic W792R mutation (substitution of a highly conserved tryptophan residue by an arginine residue at position 792) in mouse cardiomyocytes lacking endogenous cMyBP-C and studied the functional effects using three-dimensional engineered cardiac tissue constructs (mECTs). Based on complete conservation of tryptophan at this location in fibronectin type II (FnIII) domains, we hypothesized that the W792R mutation affects folding of the C6 FnIII domain, destabilizing the mutant protein. Adenoviral transduction of wild-type (WT) and W792R cDNA achieved equivalent mRNA transcript abundance, but not equivalent protein levels, with W792R compared with WT controls. mECTs expressing W792R demonstrated abnormal contractile kinetics compared with WT mECTs that were nearly identical to cMyBP-C-deficient mECTs. We studied whether common pathways of protein degradation were responsible for the rapid degradation of W792R cMyBP-C. Inhibition of both ubiquitin-proteasome and lysosomal degradation pathways failed to increase full-length mutant protein abundance to WT equivalence, suggesting rapid cytosolic degradation. Bacterial expression of WT and W792R protein fragments demonstrated decreased mutant stability with altered thermal denaturation and increased susceptibility to trypsin digestion. These data suggest that the W792R mutation destabilizes the C6 FnIII domain of cMyBP-C, resulting in decreased full-length protein expression. This study highlights the vulnerability of FnIII-like domains to mutations that alter domain stability and further indicates that missense mutations in cMyBP-C can cause disease through a mechanism of haploinsufficiency. NEW & NOTEWORTHY This study is one of the first to describe a disease mechanism for a missense mutation in cardiac myosin-binding protein C linked to hypertrophic cardiomyopathy. The mutation decreases stability of the fibronectin type III domain and results in substantially reduced mutant protein expression dissonant to transcript abundance.


Genomics ◽  
1999 ◽  
Vol 62 (3) ◽  
pp. 385-394 ◽  
Author(s):  
Jo Perry ◽  
Kieran M. Short ◽  
Justyna T. Romer ◽  
Sally Swift ◽  
Timothy C. Cox ◽  
...  
Keyword(s):  

2005 ◽  
Vol 350 (4) ◽  
pp. 776-789 ◽  
Author(s):  
Sean P. Ng ◽  
Ross W.S. Rounsevell ◽  
Annette Steward ◽  
Christian D. Geierhaas ◽  
Philip M. Williams ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document